Anika Therapeutics/$ANIK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anika Therapeutics
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Ticker
$ANIK
Sector
Primary listing
Employees
235
Headquarters
Website
ANIK Metrics
BasicAdvanced
$204m
-
-$0.78
0.23
-
Price and volume
Market cap
$204m
Beta
0.23
52-week high
$16.24
52-week low
$7.87
Average daily volume
71k
Financial strength
Current ratio
4.463
Quick ratio
3.186
Long term debt to equity
17.77
Total debt to equity
17.77
Profitability
EBITDA (TTM)
-6.86
Gross margin (TTM)
58.59%
Net profit margin (TTM)
-9.52%
Operating margin (TTM)
-10.54%
Effective tax rate (TTM)
-7.97%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-4.14%
Return on equity (TTM)
-7.85%
Valuation
Price to revenue (TTM)
1.869
Price to book
1.55
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
132.585
Free cash flow yield (TTM)
0.75%
Free cash flow per share (TTM)
0.116
Growth
Revenue change (TTM)
-0.68%
Earnings per share change (TTM)
-79.89%
3-year revenue growth (CAGR)
-9.62%
10-year revenue growth (CAGR)
1.54%
3-year earnings per share growth (CAGR)
-20.06%
10-year earnings per share growth (CAGR)
-9.95%
What the Analysts think about ANIK
Analyst ratings (Buy, Hold, Sell) for Anika Therapeutics stock.
ANIK Financial Performance
Revenues and expenses
ANIK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs